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We performed a retrospective review of medical records of patients seeking genetic counseling for mitochondrial disease at
our clinic between 2004 and 2015. Of a total of 31 adult subjects (male to female ratio= 1 : 2.1; mean age at first visit 40
years), 27 (87.1 %) underwent genetic testing. The results of the genetic testing revealed a gene mutation causing the mito-
chondrial disease in 20/27 (74.1 %) subjects. The mutation detection ratio in blood samples from symptomatic subjects was
17/22 (77.3 %). The mutation detection ratio differed according to family history of mitochondrial disease. Of the 31 sub-
jects, 13 (42.0 %) learned that they had at-risk family members based on the results of their own genetic testing. Eight female
subjects who were single or without a child or pregnant underwent genetic counseling to obtain a precise diagnosis and iden-
tify the genetic cause based on a detailed family history and other medical information. The genetic cause in these cases was
usually not identified. Even in the case of a precise diagnosis, there may not be sufficient natural history information, which
makes presymptomatic and prenatal genetic testing difficult. For subjects with mitochondrial disease and their families, un-
certainty about their future leads to great emotional stress. Our findings indicate the importance of providing clear informa-
tion about the disease and its uncertainties, empathetically listening to the patients, and assisting patients with the process of
adapting to their situation. Long-term follow-up is necessary to track changes in symptoms or in family situations, as well as
to detect new cases.
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Introduction
Mitochondrial disease is a clinically heterogeneous group
of disorders resulting from dysfunction of the mitochon-
drial respiratory chain１）. Mitochondria are present in all
eukaryotic cells except red blood cells and generate most
of the adenosine triphosphate in the cell. Mitochondrial
dysfunction is an important cause of human disease, es-
pecially in organs and tissues with high energy require-
ments. Each human cell contains hundreds of mitochon-
dria that have approximately 5 to 10 copies of circular
mitochondrial DNA ( mtDNA ) comprising 16,568 bp.
The mtDNA encodes 37 genes: 13 for subunits of respi-
ratory complexes I, III, IV, and V; 22 for mitochondrial
transfer RNA; and 2 for ribosomal RNA. When an egg
cell is fertilized by sperm, the paternal mitochondria are
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marked with ubiquitin to select them for later destruction
inside the embryo. Therefore, mtDNA usually come from
only the egg. The presence of identical copies of mtDNA
in a cell or tissue is called “homoplasmy”２）. In contrast,
the presence of more than one type of mtDNA in a cell or
tissue is called “heteroplasmy”. When the percentage of
mutated mtDNA exceeds a critical threshold, mitochon-
drial disease results３）４）. As the percentage of mutated
mtDNA varies among organs and tissues, detection of
mutated mtDNA in blood specimens may be difficult,
and it is thus sometimes necessary to obtain specimens of
the muscle or affected tissue. The common A3243G mu-
tation occurs in coding region of a mitochondrial transfer
RNA gene. This mutation is associated with several mi-
tochondrial diseases, including mitochondrial encephalo-
myopathy, lactic acidosis, and stroke-like episodes
(MELAS) and diabetes mellitus５）. The A3243G point
mutation resulted in severe respiratory chain deficiency.
Another common mutation in the MTTE gene, T14709C,
is associated with maternally inherited diabetes and deaf-
ness６）.
The vast majority of the 1,500 proteins composing mi-
tochondria are synthesized from nuclear gene transcripts,
but 13 essential subunits are encoded by mtDNA. There-
fore, the genetic cause of mitochondrial disease may be a
defect of the nuclear DNA or the mtDNA. The defect
may be inherited in autosomal recessive, autosomal
dominant, or X-linked manner, with maternal inheri-
tance７）. Mitochondrial disease may involve multiple or-
gans, and present at any age with a varied symptomatol-
ogy as well as a varied clinical course. Despite pa-
thologic, biochemical, and genetic testing, the genetic
cause is detected in only half of the patients with a sus-
pected mitochondrial defect. If the genetic cause of the
disease is not identified, genetic counseling is difficult
due to genetic heterogeneity. Here we report a summary
of our genetic counseling experience of patients with mi-
tochondrial disease, and discuss critical issues.
Subjects and Methods
Subjects were 31 adults who visited the Institute of
Medical Genetics, Tokyo Women’s Medical University
between 2004 and 2015, and underwent genetic counsel-
ing or medical examination for mitochondrial disease.
Data regarding age, sex, consultation motive, discus-
sions, symptoms, family history, and the results of ge-
netic testing, were retrospectively collected from the
medical records. All studies were conducted in accor-
dance with the Declaration of Helsinki and approved by
the ethics committees.
Results
The flow of genetic counseling related to mitochondrial
disease throughout this study is shown in Fig. 1. There
were 31 subjects (10 men, 21 women) with a mean age at
first visit of 40 years (range 21-61) (Table 1, 2) . The
consultation motive was “diagnosis of symptomatic case”
in 22 (71.0 %) cases, “presymptomatic genetic testing” in
5 (16.1 %), “provision of disease information” in 3 (9.7
%), and “estimation of recurrent risk in family” in 1 (3.2
%). Of the 27 subjects with symptoms or who were pre-
symptomatic, a mutation was detected in 20 (74.1 %)
subjects, including two presymptomatic cases, but no
mutation was detected in 7 (25.9 %) cases, including two
presymptomatic cases. Specimens collected for genetic
testing were only peripheral blood in 22, peripheral blood
and skeletal muscle in 2, skeletal muscle in 2, and periph-
eral blood and kidney in 1. The mutation detection rate of
genetic testing using only peripheral blood was 19/22
(86.4 %), and the median age at genetic testing was 42
years (21-58). The mutation detection rate of genetic test-
ing using another affected tissue was 1/5 (20.0 %). If no
information of familial mutation was available, we first
examined the 3243 mtDNA point mutation. If no 3243
mtDNA mutation was detected, we used other detection
methods, including mtDNA full-sequencing, long polym-
erase chain reaction, or Southern blot analysis for
mtDNA copy variants.
Gene mutations were detected in cases 18 of 23 symp-
tomatic subjects (excluding 4 subjects examined before
symptoms manifested) with a family history consistent
with maternal inheritance (e.g., similar diseases in chil-
dren and mother, maternal grandmother, maternal grand-
parents, siblings, or women), and gene mutations were
not detected in sporadic cases, cases No. 17-21, indicat-
ing a family history not consistent with maternal inheri-
tance. The final gene mutation detection ratio for each
symptom was as follows: diabetes+deafness 93.3 % (14/
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Fig.　1　Flow of treatment and genetic counseling for mitochondrial diseases
Genetic Counseling (continued support䠅
䐟 Examination, medication
䐠 Provide latest medical information 
䐡 Psychological counseling 
Prior to Visit
䠍䠊Collect information before visit: 
䐟 Details of consultation (name of disease, symptoms, reason for visit, brief family history)
䐠 Client (companions, if any) 
䠎䠊Advance preparation 䠖䐟 Prepare tables, documents explaining terms for information details
䐠 Always collect latest medical information
At Visit: 䠖䐟Make arrangements with other persons so that undue psychological stress is not placed on client  
䐠 Participation of certified genetic counselors, other professionals besides clinical geneticist physicians
䐡 Secure private space 
䠍䠊Questions 䠖䐟Medical history from patient (progress of symptoms, diabetes, deafness, muscle symptoms, developmental
retardation, convulsions, arrhythmia, and others) 
䐠 Create pedigree chart based on family history from patient and estimate genetic formation (maternal inheritance, 
Mendelian inheritance) 
䠎䠊Exam䠖䐟 Body measurement (short stature, emaciation, if any; BMI calculation)
䐠 General physical exam, decline in muscle strength, atrophy, if any  
䠏䠊Tests䠖䐟 General blood and urine tests, blood and cerebrospinal fluid lactate and pyruvate values, brain imaging, physiological
tests, biopsy pathology tests) 
Genetic Counseling (before genetic tests)
䐟 Details of test 
mtDNA mutation screening ĺestablished causal gene analysis, mt, nuclear ĺWotal exome analysis  
selection of samples, mtDNA/nuclear DNA subjects, test methods, time required for tests 
䐠 Limits to understanding reliability of tests 
䐡Mutations sometimes unrelated to basis for predicting future symptoms
䐢 Possibility of link to diagnosis of blood relative 
Genetic Counseling (after genetic testing) 
䐟 Conceivable diagnostic name, symptoms and other natural history 
䐠 Heredity, recurrence rate for next child and family 
䐡 Patient support groups, social welfare system, other available social resources 
䐢 Plans for providing information to at risk family members depending on situation
ͤ pay special attention to explanation of details for single women and women of childbearing age 
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Table　1　List of Clients
No. Age Sex Details of consultation
Familial  
estimate person 
at risk
Noteworthy 
status
Symptoms
Diabetes Onset age of diabetes Deafness Others
1 29 M DC Confirmed … + 24 - Tinnitus, decreased muscle force
2 36 F DC Confirmed … + 35 + Developmental retardation, low birth weight, 
cerebral palsy, headache 
3 47 F DC Confirmed … + 47 + Renal symptoms
4 58 M DC None … + 31 - Decreased muscle strength, renal symptoms, 
retinopathy, childhood acetonemic vomiting
5 35 F DC Likely … + 19 + …
6 22 F DC None Unmarried + 22 + Short stature
7 26 F DC None No children + 21 - Tinnitus
8 47 M DC None … + 27 + Tinnitus, autonomic disorder, codeine addiction
9 44 F DC None … + 32 + Short stature, apoplectic seizures, headache
10 42 M DC None … + 27 + Convulsions, stenocardia, unconsciousness, 
arrhythmia
11 47 M DC Likely … + 32 + BMI 15～ 16
12 55 F DC Likely … + 25 + …
13 58 F DC Confirmed … + 22 + Myocardiopathy
14 57 F DC Likely … + 46 + Renal symptoms
15 40 F DC None … + 25 + Renal symptoms
16 57 F DC Likely … + 42 + Short stature, emaciation, decline in muscle force 
17 48 M DC None … + 43 - Renal symptoms
18 27 M DC None … - … - Convulsions, dizziness, ophthalmoplegia externa, 
arrhythmia 
19 42 F DC Likely … - … - Epilepsy, arrhythmia 
20 45 M DC Likely … + 32 + Decline in muscle strength, renal symptoms, 
ophthalmoplegia externa, decline in visual acuity 
21 21 F DC None Unmarried - … - Renal symptoms
22 32 F DC None Pregnant GDM 32 + Tinnitus, renal symptoms, headache 
23 33 F DBO None No children → - … - …
Pregnancy → +
24 26 M DBO None … - … - …
25 27 M DBO None … - … - …
26 53 F DBO None … - … - …
27 33 F DBO None No children - … - …
28 39 F DBO Likely … + 27 + Depression
29 29 F IP None Unmarried + 18 + …
30 25 F IP None No children - … - Arrhythmia
31 61 F RRE Likely … - … - …
BMI, body mass index; DBO, diagnosis before onset; DC, diagnosis confirmed; F, female; GDM, gestational diabetes mellitus; IP, information pro-
vided; M, male; RRE, recurrence rate estimate.
15), diabetes 89.5 % (17/19), muscle symptoms 75.0 %
(3/4), nephropathy 57.1 % (4/7), short stature 100 % (3/
3), tinnitus 100 % (3/3), convulsions 33.3 % (1/3), ar-
rhythmia 33.3 % (1/3), headache 100 % (2/2), and oph-
thalmoplegia externa 0 % (0/2) . Median age at onset
when mutations were detected and time of onset of dia-
betes was 27. Diabetic symptoms manifested after testing
and pregnancy were confirmed in case No.19 who was
examined before symptoms of mitochondrial disease ap-
peared and in whom the 3243 mutation was detected.
When diagnosis of the subject or the proband was con-
firmed, there were 13 subjects (42.0 %) who had family
members at risk. Of these, 4 subjects (30.8 %) in particu-
lar had family members in whom mutations were theo-
retically “confirmed” when the subject or their proband
was diagnosed. The subjects included 8 women (25.8 %)
who were single, without children or pregnant.
During genetic counseling, the clients made remarks,
such as “What will happen when I get older?”, “I am
worried about what will happen in the future”, “If I have
mitochondrial disease, most likely this will be passed on
to my children and I don’t know what symptoms will ap-
pear”. During the course of the visit, comments such as
“I can handle the disease, but I don’t want to pass this
10
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Table　2　Client List (continued) 
No.
Test findings Family
 history
Genetic test
 Lactate value (mg/dl) (source) Biopsy Other Results Specimen
1 16.4 (cerebrospinal fluid) Muscle T14709C T14709C Blood
2 43.8 (cerebrospinal fluid) Muscle … + A3243G Blood
3 19.3 (blood) Liver … + A3243G Blood
4 … Muscle … + A3243G Muscle
5 … … … + A3243G Blood
6 … … Anti-GAD antibodies <0.3 + A3243G Blood
7 Normal … Cerebellar atrophy + A3243G Blood
Anti-GAD antibodies <0.3
8 … … … + A3243G Blood
9 … … … + A3243G Blood
10 … … … + A3243G Blood
11 … … … + A3243G Blood
12 … … … + A3243G Blood
13 … … … + A3243G Blood
14 … … … + A3243G Blood
15 … … … + A3243G Blood
16 Normal … … + A3243G Blood
17 … … …  * +/- Unclear Blood
18 … RRF in muscle, various size type 1 
fibers in biopsy 
… … Unclear Fluid, muscle
19 17.8 (cerebrospinal fluid) Myogenic changes in muscle Old infraction in cerebellar 
hemisphere
… Unclear Fluid, muscle
20 31 (blood) RRF in muscle … … Unclear Muscle
21 25.7 (blood)  Mitochondrial accumulation in liver … … Unclear Blood, kidney
22 29.8 (cerebrospinal fluid) Liver Anti-GAD antibodies <=1.3 … Not carried out …
23 … … … + A3243G Blood
24 … … … + A3243G Blood
25 … … … A3243G Negative Blood
26 … … … A3243G Negative Blood
27 … … … A3243G Not carried out …
28 … … … + Not carried out …
29 … … … + A3243G Blood
30 … … … + A3243G Blood
31 … … … + Not carried out …
+/-, maternal diabetes and paternal nephropathy; RRF, ragged red fibers.
disease to my child. I want this to stop with me”, “I can
accept this as long as the diagnosis for myself, but I am
worried about passing this on to my child”, “It is difficult
for me to think that there is a 100 % chance that the child
in my womb will have a mitochondrial disease. I can
give birth to a healthy child, can’t I? Things will be all
right, won’t they?”, and other emotional concerns were
expressed by female clients.
Discussion
In this study, gene mutations were detected in 18 (78.3
%) of 23 symptomatic subjects. In general, the mtDNA
mutation ratio for each tissue differs８） and it is well-
known that the mutation rate in the blood is low. Al-
though the affected organs and the skeletal muscle should
be used as samples in genetic testing, the mutation detec-
tion ratio in this study based on analysis of symptomatic
subjects using blood samples was 77.3 %. In addition, in
mutation-positive symptomatic subjects, 17 peripheral
blood samples (94.4 %) and 1 muscle sample (5.6 %)
were obtained. In addition, the overall rate of complica-
tions of diabetes in this study was high at 71.0 % (22/31),
and many subjects had histories consistent with mater-
nally inherited diabetes and deafness (MIDD; #520000).
Nonetheless, it is impossible to deny the influence of se-
lection bias due to the presence of departments at this
hospital specializing in the treatment of diabetes. Al-
though there was an intense focus on patients for whom a
detailed clinical history was obtained in advance, who
11
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had a family history not inconsistent with maternal in-
heritance as well as negative autoantibodies, juvenile on-
set, complications of deafness and other diagnostic char-
acteristics, these were assumed not to be linked to a com-
paratively high mutation detection ratio. Thus far, A3243
G mutations９）, T14709C mutations６）, C3256T, and other
mtDNA partial deletions１０）are reported to be causative in
diabetes related to mitochondrial disease. The mutations
detected in patients with diabetic complications in this
study were as follows: A3243G mutation in 16/17 sub-
jects and T14709C mutation in 1 subject. These muta-
tions were the same as those reported for MIDD. In mito-
chondrial diabetes, it is estimated that mutant beta-cells
initially display reduced stimulus-secretion coupling, fol-
lowed by beta-cell loss １１）. Mitochondrial diabetes is also
associated with decreased oxidative phosphorylation and
fatty acid oxidation in insulin sensitive tissues１２）. Based
on these findings, we first studied all the A3243G muta-
tions in subjects for whom maternal inheritance was clear
and clinical mitochondria diabetes was suspected. In ad-
dition, we initially did not select a highly invasive
method for sample collection. We considered that blood
sample collection rather than more invasive specimen
collection was a reasonable as long as we informed the
patient of the possibility of a low mutation detection rate
when obtaining informed consent from the patient.
Mitochondrial disease could not be completely ruled
out in five subjects in this study in which a mutation was
not detected. First, even if the mtDNA contained a muta-
tion, it is possible that the mutation analysis parameters
were insufficient or that the specimen tissue was inade-
quate. Next, in the five subjects, there was no family his-
tory suggesting maternal inheritance, so the cause of the
mitochondrial disease could have been a nuclear gene,
but nuclear genes were not examined in this study. In a
future study, we will widen the parameters of the mtDNA
mutation analysis, adding a nuclear gene test, and vary-
ing the sample tissues so that the mutations can be de-
tected.
Symptoms will likely manifest if the mtDNA mutation
exceeds a particular threshold. Confirmation of a mtDNA
mutation does not necessarily mean that the subject will
develop symptoms, as reported previously１３）. For patients
with mitochondrial disease, as well as their families, un-
certainty (e.g., what will happen to them given their pre-
sent symptoms, what type of symptoms will manifest,
when will the symptoms manifest, how their children and
family will be affected, and the fact that they do not
know what lies ahead) is a source of great stress. People
seeking genetic counseling should be given clear infor-
mation about the disease as well as its uncertainties and
must be supported during the process of receiving and
understanding information about the uncertainties.
Five subjects received genetic counseling regarding
symptoms before the onset of any disease. When the
cause of familial mitochondrial disease is maternal in-
heritance based on mtDNA mutations, the mutation pro-
portion differs in each tissue. As a result, whether or not
mutations are detected in at-risk subjects who do not pre-
sent with symptoms, it is difficult to predict the future
onset of disease in these subjects or to make detailed pre-
dictions about their symptoms. In addition, even when it
is possible to make predictions and assumptions about
the disease, the fact that there are no preventive measures
or basic methods of treatment is a problem for diagnosis
before the onset of a serious illness. Among mitochon-
drial diseases, however, symptoms vary so that informa-
tion regarding the clinical symptoms of those in the fam-
ily who are sick may not be of use in the diagnosis of
blood relatives. Many at-risk people who are free of
symptoms request a presymptomatic examination of at-
risk persons. Even after we have explained the details of
inheriting a mitochondrial disease and the uncertainties
inherent in the genetic testing, we carried out the genetic
testing if the demand was particularly forceful. After the
A3243G mutation was detected in subject No.23, she be-
came pregnant and was diagnosed with diabetes, so the
genetic information was useful for selecting an institution
for childbirth. While presymptomatic diagnosis is not the
best option for all subjects, this information can be useful
in managing the medical records for women who are at
risk of developing the disease during pregnancy.
While this does not involve presymptomatic diagnosis,
sometimes the presence of a mtDNA mutation in the
mother and siblings with no symptoms or very mild
symptoms is ascertained theoretically by confirming the
mutation in a proband. In this study, 42.0 % of those who
came for treatment had a family member at risk based on
their own diagnosis, and subjects who were diagnosed or
for whom the presence of mutations was confirmed theo-
12
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retically accounted for 30.8 % of these. Although there
are many cases in which an unexpected diagnosis can
bring about intense upset, providing client treatment in-
formation to a person assumed to have a mtDNA muta-
tion and to persons at risk in the family is beneficial for
the future medical care of that person. As a result, when a
client undergoes genetic testing, the client should be told
beforehand that it is possible to partially infer genetic in-
formation regarding a blood relative based on the test re-
sults for the client and sometimes that information should
be shared with the family member at that time.
In this study, women accounted for approximately
two-thirds of those who requested a consultation. In par-
ticular, women of childbearing age who were single,
without children, and pregnant accounted for 25.8 % of
the women. There were sex differences among those who
came for consultation, and among the men the consulta-
tions involved their own diagnosis in all cases. Women,
however, came regarding treatment for their family mem-
bers rather than for themselves. There is a common mis-
conception that mitochondrial disease is inherited mater-
nally and it may be that this affected their motivation to
come to the hospital as well as the details of the consulta-
tion. Actually, mtDNA contain about 5 to 10 times more
mutations than nuclear DNA and 1 in 200 newborns has
a mtDNA mutation, which accounts for 1/5 of all neona-
tal mutations１４）. As a result, even though there are muta-
tions in the mtDNA, they are by no means restricted to
those inherited from the mother. Some mitochondrial dis-
eases are caused by mutations in the nuclear DNA. Car-
rying the mutations is not the fault of the individual and
the individual should not feel guilty. Realistically, how-
ever some clients may feel a baseless guilt for their situ-
ation. Particular attention is required for women and even
if a couple comes in for a consultation, they may need to
be seen separately with the woman given priority when
her partner is present.
Almost none of the consultations were concerned with
estimating the rate of recurrence for the next child and an
examination before giving birth. When heteroplasmy re-
lates to the manifestation of symptoms in the mtDNA
mutations that are inherited from the mother, it is diffi-
cult to make a diagnosis prior to giving birth and we be-
lieve that in these cases the consultation should concen-
trate on providing information about seeking a highly
specialized medical institution for the birth. This is tech-
nically possible when there is an onset with homoplasmy,
as is the case with mt8993 mutations even when inherited
from the mother１５）１６）, and when nuclear gene mutations,
which have been reported more than 200 times１７）, are the
cause. The need for genetic counseling in prenatal exami-
nations and in the perinatal period will most like increase
as the causes of mitochondrial disease are confirmed.
Conclusions
We reported on genetic counseling experience relating to
mitochondrial disease carried out at this center from
April 2004 to November 2015. Thirty-one adults with a
mean age of 40 years came for counseling. Genetic test
results were confirmed in 74.1 % (20/27) of the subjects.
The mutation detection ratio in blood samples obtained
from those with symptoms was 77.3 % (17/22 subjects).
Of the 31 subjects who came for counseling, 13 (42.0 %)
had a family member who was at risk based on the cli-
ent’s diagnosis. Eight (25.8 %) of the 31 subjects who
came for counseling were women that were single, child-
less, or pregnant. We believe that it is extremely impor-
tant to evaluate all of the symptoms to provide a detailed
history relating to mitochondrial disease and to provide
genetic counseling that is appropriate for confirming an
exact diagnosis based on clinical information and to con-
firm the pathogenesis. In some cases, the pathogenesis
was not identified, and even when it was identified, it
was often difficult to provide insight as well as to follow
the progress of the disease. As a result, we believe that it
is extremely important to organize clear information
about the disease and its uncertainties, to empathetically
listen to the subjects, and to assist the patients with the
process of adapting to their situation. Long-term follow
up is indispensable, as is follow-up of new patients in the
client’s family and continuous involvement in these in-
teractions.
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